Laplace Interventional Raises Funds to Support Development of Transcatheter Tricuspid Valve Technology

September 1, 2021—Laplace Interventional, a St. Paul, Minnesota–based medical device company developing a transcatheter tricuspid valve, announced that it has closed on a Series A financing round. The company is developing a prosthetic transcatheter valve to treat patients with tricuspid regurgitation. The $7.9 million financing will fund Laplace Interventional’s efforts to achieve its preclinical milestones for the device.

According to the company, the financing round was led by a nondisclosed major strategic investor along with a significant investment from ShangBay Capital, an early-stage medical device investor, and other investors including Mayo Clinic. The company also announced the addition of two Directors to its Board including William Dai, Founding Managing Partner at ShangBay Capital.

“I am very excited to partner with our strategic investor and ShangBay Capital in further developing Laplace’s technology,” commented Ramji Iyer, Founder and CEO of Laplace Interventional, in the announcement. “Together we will pursue and achieve our primary objective to significantly improve the standard of care for patients suffering from tricuspid regurgitation.”

William Dai added, “We are very excited about Laplace’s novel transcatheter replacement technology and its strong potential to improve the outcomes of patients with tricuspid regurgitation.”